Sunovion CTH-302 – Oral Apomorphine vs. Apomorphine injection.
The aim of this research is to see how movement may be improved by taking oral Apomorphine and evaluate this method of delivery against the sub-cutaneous injection of Apomorphine which is currently available for people with Parkinson’s.
25 people diagnosed with Parkinson’s. You must have a good response to Levodopa, which you should be taking at least 3 times a day and experience “OFF” periods.
You will first go through a screening process where you will be assessed for your suitability to take part in the full research trial. At this screening visit you will have the opportunity to ask questions, give your consent, and a range of assessments will be performed.
You will be required to take both oral Apomorphine and subcutaneous Apomorphine injection during the course of the study.
For full information about the research:
Please read the Participant Information Sheet.
If you would like to understand more about the trial visit structure, read the trial flow diagram.
Sunovion Pharmaceuticals Inc.
Kings College Hospital
Denmark Hill
Parkinson's research facility
London
SE5 9RT
United Kingdom
Imperial College Healthcare NHS Trust
Charing Cross Hospital
Fulham Road
Hammersmith
W6 8RF
United Kingdom
Queens medical centre Nottingham university hospitals NHS trust
Derby Road
Nottingham
NG7 2UH
United Kingdom